Doxorubicin + Cyclophosphamide + Paclitaxel + Sorafenib
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
May 1, 2007 → Apr 1, 2011
NCT ID
NCT00544167About Doxorubicin + Cyclophosphamide + Paclitaxel + Sorafenib
Doxorubicin + Cyclophosphamide + Paclitaxel + Sorafenib is a pre-clinical stage product being developed by Bayer for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00544167. Target conditions include Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00544167 | Pre-clinical | Completed |
Competing Products
20 competing products in Breast Cancer